By Fineline Cube 
3SBio Inc. (HKG: 1530) conditionally agreed to place 105,169,500 shares at HK$29.62 per share, raising over HK$3.1 billion through an exclusive placing agent to not fewer than six investors.
Placement Summary & Allocation
| Attribute | Details |
|---|---|
| Company | 3SBio Inc. (1530.HK) |
| Shares Placed | 105,169,500 |
| Price per Share | HK$29.62 |
| Total Proceeds | HK$3.1 billion |
| Investors | Minimum six places |
Proceeds Allocation:
- 80% R&D: Clinical studies in China and US, indication expansion for commercialized drugs, global infrastructure
- 20% Operations: Support ongoing operations and strategic plans
Key Pipeline Candidates Funded
| Program | Target | Stage | Focus |
|---|---|---|---|
| 705 | PD1/HER2 bispecific | Clinical | Solid tumors |
| 706 | PD1/PDL1 bispecific | Clinical | Immuno‑oncology |
| 008 | B7H3/IL15 bispecific | Clinical | Solid tumors |
| 59 | MUC17/CD3/CD28 trispecific | Clinical | Oncology |
| 626 | BDCA2 antibody | Clinical | Autoimmune |
| 627 | TL1A inhibitor | Clinical | Inflammatory diseases |
Commercial Drug Expansion:
- TPIAO (TPO): Thrombopoietin for indication expansion
- EPIAO (EPO): Erythropoietin for new indications
Strategic Context & Market Implications
- Financing Timing: Strengthens cash position amid biotech valuation recovery
- Pipeline Depth: Six clinical-stage bispecific/trispecific programs position 3SBio as leader in next-gen biologics
- Global Ambition: US clinical trials for multiple assets signal international expansion strategy
- Infrastructure Investment: Global R&D and manufacturing capabilities support long-term growth
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the use of proceeds, pipeline advancement, and strategic plans. Actual results may differ due to clinical, regulatory, and market conditions.-Fineline Info & Tech